Former Senior Vice President, Chief Commercial Officer · Vanda Pharmaceuticals Inc. (VNDA)

Gian Reverberi

A named executive officer of Vanda Pharmaceuticals in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$2,296,319

Salary $519,071Stock awards $618,600

FY2018: $2,275,881

2nd of 5 named executive officers at Vanda Pharmaceuticals by FY2019 total.

5 named officers on file for Vanda Pharmaceuticals, FY2019

Gian Reverberi’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • VNDA’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vanda Pharmaceuticals’s whole pay program stands against its peers

  • Vanda Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VNDA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2020 (DEF 14A).

Free

Get Gian Reverberi’s full pay file as a PDF — free

More than this page: up to 10 years of Gian’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Gian Reverberi compensation by year

Vanda Pharmaceuticals Summary Compensation Table · all 4 fiscal years held
In US dollars, as Vanda Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$472,182$486,553$495,321$519,071
Bonus$0$0$0$0
Stock awards$435,000$435,000$618,600$618,600
Option awards$548,800$548,800$805,077$805,077
Non-equity incentive$212,482$203,622$278,618$273,291
Pension and deferred compensation$0$0$0$0
All other$66,030$81,595$78,265$80,280
Total$1,734,494$1,755,570$2,275,881$2,296,319

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vanda Pharmaceuticals Inc. DEF 14A filed April 22, 2020, accession 0001347178-20-000009, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vanda Pharmaceuticals Inc. filed document, accession 0001347178-20-000009. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2020.

$1.7M
$1.8M
$2.3M
$2.3M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU15,000$246,150—
RSU12,500$205,125—
Option21,875—$14.50
Option2,917—$7.94

Per the Outstanding Equity Awards at Fiscal Year-End table in Vanda Pharmaceuticals Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Vanda Pharmaceuticals’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Mihael PolymeropoulosPresident and Chief Executive Officer$4,278,137
Gian Reverberi · this pageFormer Senior Vice President, Chief Commercial Officer$2,296,319
James KellyFormer Executive Vice President, Chief Financial Officer and Treasurer$2,248,410
Timothy WilliamsSenior Vice President, General Counsel and Secretary$2,022,854
Gunther BirznieksSenior Vice President, Business Development$2,010,821

The full Vanda Pharmaceuticals compensation record

free company brief

This page is one person within Vanda Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vanda Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vanda Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gian Reverberi's compensation dossier · One-time report. No refunds.